Advertisement


Richard Finn, MD, on Advanced Breast Cancer: New Data on Palbociclib Plus Letrozole From PALOMA-2

2022 ASCO Annual Meeting

Advertisement

Richard Finn, MD, of the Geffen School of Medicine at UCLA and the Jonsson Comprehensive Cancer Center, discusses analyses from the PALOMA-2 trial on overall survival with first-line palbociclib plus letrozole vs placebo plus letrozole in women with ER-positive/HER2-negative advanced breast cancer. The study met its primary endpoint of improving progression-free survival but not the secondary endpoint of overall survival. Although patients receiving palbociclib plus letrozole had numerically longer overall survival than those receiving placebo plus letrozole, the results were not statistically significant (Abstract LBA1003).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The development of CDK 4/6 inhibitors in advanced breast cancer have really been a hallmark advance for the management of that group of patients. The first CDK 4/6 inhibitor was palbociclib, based on the PALOMA-1 study, which demonstrated a significant improvement in progression-free survival for that population. Since that time, there's been seven randomized studies with CDK 4/6 inhibitors, which have confirmed that observation. The PALOMA-2 study was the confirmatory study with palbociclib and letrozole versus placebo and letrozole, whose primary endpoint was to improve progression-free survival. And we demonstrated that, and that has served for the global approval of palbociclib in this population of patients. Now we are presenting the overall survival data from that study. This has been long awaited and with seven and a half years of follow-up, we're showing that there is a numerical improvement in overall survival, but this does not reach statistical significance. Really, in the context of advanced breast cancer, we have seen that as a class, CDK 4/6 inhibitors have improved overall survival. Specifically in PALOMA-2, there were some challenges that limits our assessment over overall survival. Specifically, we had about a third of the patients that had missing data for overall survival at the time of our analysis. Much of that was from patients withdrawing consent, as well as patients lost to follow up. We did demonstrate though, in those groups or subgroups of patients where the dropout was less pronounced. And actually there was also a disproportionate dropout in the control arm versus the treatment arm, so when we looked at subgroups where the dropout was a little closer, we did see that there was a trend towards an improvement in overall survival with palbociclib and letrozole versus the control arm of letrozole alone. The other thing to note is PALOMA-2 included about 20% of patients who had a disease-free interval of less than one year. And when we look at the largest group of patients in our study, which are those had a disease free interval of greater than 12 months, we actually see quite significant improvement in overall survival, given it's a subgroup analysis and is being looked at retrospectively. There was also a pre-planned analysis, combining data from PALOMA-1 and PALOMA-2. And in that analysis, we see again, a strong trend towards improvement in overall survival with palbociclib. And when we look again at this group of patients who had a long disease-free interval greater than 12 months from their adjuvant treatment, again, a very strong trend towards improving overall survival. So the take home message is PALOMA-2 met its primary endpoint of improving PFS, improved objective response rate. It has maintained quality of life. And with seven and a half years of follow-up, there's no new toxicity, there's no cumulative toxicity, and when we look at the overall survival for the whole population of patients, we see that it's over 50 months, which is really striking and tells us that the incorporation of CDK 4/6 inhibitors into the management of these women is really changing the natural history of this subtype of breast cancer.

Related Videos

Breast Cancer

Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib

Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had relapsed or progressed on an aromatase inhibitor. The benefit may be predominantly in patients with PIK3CA/AKT1/PTEN pathway–altered tumors, a topic researchers continue to study in the phase III CAPItello-291 trial (Abstract 1005).

 

Colorectal Cancer
Genomics/Genetics

Michael J. Overman, MD, and Smitha Krishnamurthi, MD, on RAS Wild-Type Metastatic Colorectal Cancer: Refining Treatment Strategy

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Smitha Krishnamurthi, MD, of the Cleveland Clinic, review three abstracts, all of which enrolled patients with newly diagnosed RAS and BRAF wild-type metastatic colorectal cancer with left-sided primary tumors. The discussion centers on what the study results indicate about the use of an EGFR therapy and weighing the risk to quality of life from rash, in particular (Abstracts LBA3503, LBA3504, LBA3505).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel treatment. The findings suggest that LuPSMA is a suitable option for this population, with fewer adverse events, higher response rates, improved patient-reported outcomes, and similar overall survival compared with cabazitaxel (Abstract 5000).

Neuroendocrine Tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).

Multiple Myeloma

Paul G. Richardson, MD, on Multiple Myeloma: New Data on Lenalidomide, Bortezomib, and Dexamethasone, With or Without ASCT

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant (ASCT) and lenalidomide maintenance to disease progression resulted in the longest median progression-free survival reported for each approach, and a highly significant difference in progression-free survival in favor of early transplant. While overall response rates were similar, rates of MRD favored early transplant also, but toxicity was greater and quality of life was transiently but significantly diminished. No overall survival advantage has been observed to date (Abstract LBA4).

Advertisement

Advertisement




Advertisement